Creating new vaccines to protect against human noroviruses
Official title: Development of novel multivalent mucosal vaccines for human noroviruses
Funded at Ohio State University · NIH-11168321 · Data updated 2026-11-12
This study is working on a new type of vaccine to help protect kids from noroviruses, which can cause nasty stomach bugs, by using parts of existing vaccines that are already approved for other illnesses.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | May 1, 2025 |
| Project end | April 30, 2030 |
| Funding year | 2025 |
| Award (this year) | $798,173 |
| NIH project number | 1R01AI183671-01A1 |
| Project ID | NIH-11168321 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children aged 0-11 years who are at risk for norovirus infections.
✕Less likely to help
Patients who are older than 11 years or those who have already been vaccinated against noroviruses may not benefit from this research.
What this research studies
This research focuses on developing innovative mucosal vaccines to combat human noroviruses, which are a leading cause of acute gastroenteritis in children. The approach involves using existing FDA-approved vaccine platforms, specifically those for rotavirus and measles/mumps/rubella, to create a new vaccine that can induce strong immune responses. By inserting specific genes from the norovirus into these vaccine platforms, the goal is to provide broad protection against various strains of the virus. This research aims to establish a viable vaccine option where none currently exists.
Why it matters
Potential benefit: If successful, this research could lead to effective vaccines that significantly reduce the incidence of norovirus infections in children.
How similar studies have gone: Previous research has successfully developed live attenuated vaccines for other viruses, suggesting that this approach may also be effective for noroviruses.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Li, Jianrong — Ohio State University
- Study coordinator: Li, Jianrong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.